Edap Tms SA (EDAP) — SEC Filings
Edap Tms SA (EDAP) — 31 SEC filings. Latest: 10-K (Mar 25, 2026). Includes 25 6-K, 2 20-F, 2 SC 13G/A.
Overview
Edap Tms SA (EDAP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 25, 2026: EDAP TMS SA, a medical technology company, reported a market value of voting and non-voting common equity held by non-affiliates of $61,845,277 as of June 30, 2025. The company is strategically realigning its business to focus exclusively on its proprietary High Intensity Focused Ultrasound (HIFU) t
Sentiment Summary
Across 31 filings, the sentiment breakdown is: 15 bullish, 16 neutral. The dominant filing sentiment for Edap Tms SA is neutral.
Filing Type Overview
Edap Tms SA (EDAP) has filed 1 10-K, 1 8-K, 25 6-K, 2 20-F, 2 SC 13G/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (31)
Risk Profile
Risk Assessment: Of EDAP's 25 recent filings, 0 were flagged as high-risk, 7 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Ploussard G.
- Yeh et al.
- Rosta G.
- Olivares R.
- Rischmann P.
- Kaufmann B
- Ken Mobeck
- KEN MOBECK
- Ken Moebck
- Ken Mobek
- Glen French
- Joshua H. Levine
- Fran Schulz
Industry Context
EDAP TMS operates in the highly competitive medical technology sector, specifically within therapeutic ultrasound and energy-based devices. The company's strategic focus on High Intensity Focused Ultrasound (HIFU) positions it within a niche but growing area of minimally invasive treatments. Key trends include the increasing demand for non-invasive procedures, the integration of AI in medical devices for enhanced visualization and treatment planning, and the expansion of indications for existing technologies into new disease areas like endometriosis.
Top Tags
medical-devices (6) · medical-device (5) · earnings (4) · financial-results (4) · revenue-growth (4) · foreign-private-issuer (3) · financing (3) · prostate-cancer (3) · board-appointment (3) · regulatory-filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of voting and non-voting common equity held by non-affiliates | $61,845,277 | As of June 30, 2025, indicating the company's market capitalization for non-insider holdings. |
| Ordinary shares outstanding | 37,481,986 | As of March 25, 2026, representing the total number of shares in circulation. |
| FDA 510(k) clearance for Focal One | June 7, 2018 | Permitted commercialization of Focal One in the United States for prostate tissue ablation. |
| FDA Breakthrough Device designation | March 13, 2024 | Granted for Focal One for the treatment of deep infiltrating endometriosis (DIE), accelerating regulatory review. |
| CE Mark for Focal One | March 26, 2025 | Received for the treatment of posterior deep endometriosis infiltrating the rectum and surrounding structures, enabling European commercialization. |
| New FDA 510(k) clearance | November 20, 2025 | Obtained for the latest evolution of Focal One Robotic HIFU, including next-generation ultrasound imaging for AI development. |
| Patients enrolled in the HIFI study | 3,328 | The largest prospective, comparative, multi-center clinical study comparing prostate cancer treatments, demonstrating HIFU's efficacy. |
| Follow-up period for HIFI study | 30 months | Duration over which Focal One Robotic HIFU was found non-inferior to radical prostatectomy for Salvage Treatment-free Survival. |
| Patients enrolled in the FARP study | 213 | The first Randomized Controlled Trial comparing focal ablation versus robotic prostatectomy, showing non-inferiority. |
| Follow-up period for CGRD study | 10 years | HIFU demonstrated non-inferior overall survival and cancer-specific survival compared to EBRT for stage II prostate cancer. |
| Credit Facility Amount | €36.0 million | Funds to be used for research and development of robotic medical technology. |
| Focal One® Net Placement Growth | +140% | Significant year-over-year increase indicating strong market adoption |
| HIFU Revenue Growth | +76.8% | Substantial year-over-year increase in revenue from HIFU technology |
| Credit Facility Letter of Intent | 36 million Euro | Indicates potential for increased financial flexibility |
| Credit Facility | €36M | Amount intended to accelerate growth and strategic expansion |
Frequently Asked Questions
What are the latest SEC filings for Edap Tms SA (EDAP)?
Edap Tms SA has 31 recent SEC filings from Jan 2024 to Mar 2026, including 25 6-K, 2 20-F, 2 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EDAP filings?
Across 31 filings, the sentiment breakdown is: 15 bullish, 16 neutral. The dominant sentiment is neutral.
Where can I find Edap Tms SA SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Edap Tms SA (EDAP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Edap Tms SA?
Key financial highlights from Edap Tms SA's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EDAP?
The investment thesis for EDAP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Edap Tms SA?
Key executives identified across Edap Tms SA's filings include Ploussard G., Yeh et al., Rosta G., Olivares R., Rischmann P. and 8 others.
What are the main risk factors for Edap Tms SA stock?
Of EDAP's 25 assessed filings, 0 were flagged high-risk, 7 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Edap Tms SA?
Forward guidance and predictions for Edap Tms SA are extracted from SEC filings as they are enriched.